Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a caucasian population

被引:88
作者
Shipkova, M
Lorenz, K
Oellerich, M
Wieland, E
Von Ahsen, N
机构
[1] Klinikum Stuttgart, Cent Inst Clin Chem & Lab Med, D-70174 Stuttgart, Germany
[2] Univ Gottingen, Dept Clin Chem, D-3400 Gottingen, Germany
关键词
D O I
10.1373/clinchem.2005.059501
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Inosine triphosphate (ITP) pyrophosphohydrolase (ITPA) catalyzes the pyrophosphohydrolysis of ITP/dITP and xanthosine triphosphate to prevent incorporation of unusual nucleotides into RNA and DNA. Important mutations leading to enzyme deficiency are 94C > A and IVS2 + 21A > C. An association between ITPA 94C > A and adverse reactions during azathioprine treatment has been shown. To investigate the ITPA phenotype, an HPLC procedure was developed and phenotype-genotype correlations were assessed. Methods: The enzymatic conversion of ITP to inosine monophosphate (IMP) was terminated by perchloric acid and saturated dipotassium hydrogen phosphate. We quantified the IMP at 262 nm after separation on an Aqua perfect C-18 column using 20 mmol/L phosphate buffer, pH 2.5. We also genotyped samples for ITPA 94C > A and IVS2 + 21A > C by real-time fluorescence PCR. Results: The assay was linear to 3 mmol/L IMP [similar to 500 mu mol/(g Hb (.) h)] with a lower limit of quantification of 4 mu mol/L [similar to 0.5 mu mol/(g Hb (.) h)]. With IMP-enriched samples, within- and between-day imprecision was <= 3.6% and <= 4.9%, respectively, and the inaccuracy was <= 5.2%. With pooled erythrocytes, within- and between-day imprecision was 3.8% and 7.5%, respectively. ITPA activity in 130 healthy controls was between < 0.5 and 408 mu mol IMP/(g Hb (.) h). Mutant allele frequencies were 0.062 (94C > A) and 0.131 (IVS2 + 21A > C). When we used a cutoff of 125 mu mol IMP/(g Hb (.) h), phenotyping detected all 94C > A mutant cases, all 94C > A and IVS2 + 21A > C compound heterozygotes, all IVS2 + 21A > C homozygotes, and 6 of 24 IVS2 + 21A > C heterozygote-only cases. A novel IVS2 + 68T > C mutation was also found. Conclusions: The HPLC procedure provides an excellent ITPA phenotype-genotype correlation and led to the discovery of a novel IVS2 + 68T > C mutation. The method could facilitate investigation of the role of ITPA activity for drug toxicity during thiopurine therapy. (c) 2006 American Association for Clinical Chemistry.
引用
收藏
页码:240 / 247
页数:8
相关论文
共 36 条
[1]   ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression [J].
Allorge, D ;
Hamdan, R ;
Broly, F ;
Libersa, C ;
Colombel, JF .
GUT, 2005, 54 (04) :565-565
[2]  
[Anonymous], THER DRUG MONIT
[3]   Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation [J].
Breen, DP ;
Marinaki, AM ;
Arenas, M ;
Hayes, PC .
LIVER TRANSPLANTATION, 2005, 11 (07) :826-833
[4]   Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine [J].
Campbell, S ;
Kingstone, K ;
Ghosh, S .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (03) :389-398
[5]   DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency [J].
Cao, HN ;
Hegele, RA .
JOURNAL OF HUMAN GENETICS, 2002, 47 (11) :620-622
[6]   Fluorescein-labeled oligonucleotides for real-time PCR: Using the inherent quenching of deoxyguanosine nucleotides [J].
Crockett, AO ;
Wittwer, CT .
ANALYTICAL BIOCHEMISTRY, 2001, 290 (01) :89-97
[7]   Thiopurine Methyltransferase Activity Influences Clinical Response to Azathioprine in Inflammatory Bowel Disease [J].
Cuffari, Carmen ;
Dassopoulos, Themistocles ;
Turnbough, Lisa ;
Thompson, Richard E. ;
Bayless, Theodore M. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (05) :410-417
[8]   Optimizing immunomodulator therapy for inflammatory bowel disease [J].
Marla C. Dubinsky .
Current Gastroenterology Reports, 2003, 5 (6) :506-511
[9]   6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease [J].
Dubinsky, MC ;
Yang, HY ;
Hassard, PV ;
Seidman, EG ;
Kam, LY ;
Abreu, MT ;
Targan, SR ;
Vasiliauskas, EA .
GASTROENTEROLOGY, 2002, 122 (04) :904-915
[10]   INOSINE TRIPHOSPHATE PYROPHOSPHOHYDROLASE DEFICIENCY IN A KINDRED WITH ADENOSINE-DEAMINASE DEFICIENCY [J].
DULEY, JA ;
SIMMONDS, HA ;
HOPKINSON, DA ;
LEVINSKY, RJ .
CLINICA CHIMICA ACTA, 1990, 188 (03) :243-252